Literature DB >> 35847467

Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series.

Sukhpreet Poonia1, Mazen Sharaf2, Ric M Procyshyn3, Randal White4, Reza Rafizadeh5.   

Abstract

Entities:  

Year:  2022        PMID： 35847467      PMCID： PMC9245404          DOI： 10.4212/cjhp.3178

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  20 in total

1.  Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.

Authors:  Geoffrey K Isbister; Corrine R Balit; Dawson Macleod; Stephen B Duffull
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

2.  The usefulness of rating scales in patients with schizophrenia.

Authors:  W Wolfgang Fleischhacker
Journal:  Acta Psychiatr Scand       Date:  2016-06       Impact factor: 6.392

Review 3.  Is the PANSS used correctly? a systematic review.

Authors:  Michael Obermeier; Rebecca Schennach-Wolff; Sebastian Meyer; Hans-Jürgen Möller; Michael Riedel; Daniela Krause; Florian Seemüller
Journal:  BMC Psychiatry       Date:  2011-07-18       Impact factor: 3.630

4.  Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study.

Authors:  E Smeraldi
Journal:  J Affect Disord       Date:  1998-02       Impact factor: 4.839

5.  Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

Authors:  G Perrault; R Depoortere; E Morel; D J Sanger; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

Review 6.  Practical issues with amisulpride in the management of patients with schizophrenia.

Authors:  Luca Pani; José M Villagrán; Vassilis P Kontaxakis; Köksal Alptekin
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study.

Authors:  Yasin Genç; Ender Taner; Selcuk Candansayar
Journal:  Adv Ther       Date:  2007 Jan-Feb       Impact factor: 3.845

8.  Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

Authors:  A D Kashuba; A N Nafziger; G L Kearns; J S Leeder; R Gotschall; M L Rocci; R W Kulawy; D J Beck; J S Bertino
Journal:  Clin Pharmacol Ther       Date:  1998-09       Impact factor: 6.875

9.  Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland.

Authors:  Heidi Taipale; Marco Solmi; Markku Lähteenvuo; Antti Tanskanen; Christoph U Correll; Jari Tiihonen
Journal:  Lancet Psychiatry       Date:  2021-08-30       Impact factor: 27.083

10.  Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Thomas R E Barnes; Verity Leeson; Carol Paton; Louise Marston; David P Osborn; Raj Kumar; Patrick Keown; Rameez Zafar; Khalid Iqbal; Vineet Singh; Pavel Fridrich; Zachary Fitzgerald; Hemant Bagalkote; Peter M Haddad; Mariwan Husni; Tim Amos
Journal:  Ther Adv Psychopharmacol       Date:  2018-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.